Results 1 to 10 of about 1,194 (171)

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system [PDF]

Frontiers in Pharmacology
BackgroundMaribavir and valganciclovir are pharmacotherapeutic options utilized in the management of cytomegalovirus (CMV) infection post-transplantation.
Haolin Teng, Shengnan Zhang, Jinyu Yu, Faping Li   +3 more
doaj   +4 more sources

Population Pharmacokinetics and Exposure–Response Relationships of Maribavir in Transplant Recipients With First Episode or Refractory Cytomegalovirus [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Maribavir's anti‐cytomegalovirus (CMV) activity and favorable safety/tolerability profile is a welcomed addition to the CMV treatment armamentarium.
Kefeng Sun, Claudia Jomphe, Nathalie H. Gosselin, Leon Pheng, Chandrasekar Durairaj, Yaming Hang, Indranil Bhattacharya   +6 more
doaj   +3 more sources

Evaluating valaciclovir, letermovir, and maribavir safety in first-trimester human placental development [PDF]

Scientific Reports
Congenital cytomegalovirus (CMV) infection is the leading preventable cause of childhood disability, including sensorineural hearing loss and cerebral palsy in high-income countries.
Ishara Atukorala, Natasha de Alwis, Sally Beard, Swetha Raghavan, Natalie J. Hannan, Lisa Hui   +5 more
doaj   +3 more sources

Association Between Cytomegalovirus Viremia Clearance and Post-Solid Organ Transplant Mortality in Patients With Refractory Cytomegalovirus Infection: SOLSTICE Post Hoc Analysis [PDF]

Transplant International
Cytomegalovirus (CMV) infection following solid organ transplant (SOT) is associated with increased mortality risk. In the phase 3 SOLSTICE study (NCT02931539), more transplant recipients achieved CMV clearance after 8 weeks with maribavir than ...
Nassim Kamar, Robin K. Avery, Tien Bo, Joan Gu, Deepali Kumar, Oliver Witzke   +5 more
doaj   +4 more sources

Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus

Therapeutics and Clinical Risk Management, 2022
Ronak G Gandhi,1 Camille N Kotton2 1Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA; 2Infectious Diseases Division, Massachusetts General Hospital, Boston, MA, USACorrespondence: Ronak G Gandhi, Senior Attending Pharmacist ...
Ronak G Gandhi, Camille N Kotton
exaly   +6 more sources

Use of Maribavir in Adult Patients With Post-Transplant Refractory Cytomegalovirus Infection in the Real-Life Setting [PDF]

Transplant International
Maribavir is indicated for the treatment of refractory cytomegalovirus (CMV) infection/disease in patients who have undergone a solid organ transplant (SOT) or hematopoietic cell transplant (HCT).
Nassim Kamar, Fanny Vuotto, Catherine Cordonnier, Philippe Gatault, Faouzi Saliba, Faouzi Saliba, Lionel Couzi, Vincent Bunel, Vincent Bunel, Cinira Lefevre, Michèle Maric, Abdelkrim Ziad, Sophie Alain   +12 more
doaj   +2 more sources

Case report: Maribavir as salvage therapy for multidrug-resistant CMV DNAemia in a non-transplant patient with ocular cicatricial pemphigoid [PDF]

IDCases
Cytomegalovirus (CMV) is a significant cause of morbidity in immunocompromised patients, particularly those receiving chronic systemic therapy for autoimmune diseases such as ocular cicatricial pemphigoid (OCP).
Balachandran R. Vaidyanathan, Akshaya Balaji   +1 more
doaj   +2 more sources

Case Report: Maribavir for refractory cytomegalovirus viremia after renal transplantation in a child with Schimke’s immune-osseous dysplasia [PDF]

Frontiers in Immunology
Cytomegalovirus (CMV) is a major opportunistic pathogen in recipients of solid organ transplantation. Maribavir, a pUL97 protein kinase inhibitor, was approved for the treatment of refractory post-transplant CMV infection in the US in 2021.
Jia-Shuan Huang, Jia-Shuan Huang, Hong-Kai Wang, Li-Ping Rong, Xiao-Yun Jiang, Long-Shan Liu, Liu-Yi Huang, Na Zhang, Zhi-Hui Yue   +8 more
doaj   +2 more sources

Maribavir for Cytomegalovirus Infection in High‐Risk Kidney Transplant Recipients: A Case Series [PDF]

IJU Case Reports
Background Cytomegalovirus (CMV) infection remains a common complication after kidney transplantation, particularly among high‐risk donor‐seropositive/recipient‐seronegative (D+/R−) recipients.
Daiji Takamoto, Yu Shimada, Yuri Hasegawa, Takeaki Noguchi, Takashi Kawahara, Junichi Teranishi, Kazuhide Makiyama   +6 more
doaj   +2 more sources

Reversion of Val(Ganciclovir)-Resistance-Associated Mutations in Two SOT Patients with Mismatched Serostatus for CMV (D+/R-) [PDF]

Viruses
The emergence of drug-resistant cytomegalovirus (CMV) complicates viral response to therapy. We present two cases of solid organ transplant (SOT) recipients, highlighting the reversion of UL97 mutations associated with val(ganciclovir) resistance ...
Elena Seminari, Alessandra Tebaldi, Aurelia Sangani, Paola Giordani, Daniele Lilleri, Stefania Paolucci, Giulia Campanini, Elizabeth Iskandar, Fausto Baldanti, Raffaele Bruno   +9 more
doaj   +2 more sources